Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OvamiR ONT
- Development stage
- Preclinical
- Lead developer
- AptamiR Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intraperitoneal
01
Overview
OvamiR ONT is a preclinical microRNA-targeting oligonucleotide therapeutic (ONT) being developed by AptamiR Therapeutics for the treatment of epithelial ovarian cancer (EOC) and high-grade serous ovarian cancer (HGSOC). The therapeutic is designed to target the folate receptor alpha (FOLR1), which is highly expressed in ovarian cancer cells, to facilitate targeted delivery and uptake. Once internalized, OvamiR ONT modulates a network of oncogenic microRNAs that drive tumor proliferation, migration, invasion, metastasis, and epithelial-mesenchymal transition (EMT). Additionally, it is designed to sensitize tumor cells to chemotherapy, addressing the significant challenge of chemoresistance in advanced ovarian cancer.
- Other names
- OvamiR
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on OvamiR ONT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OvamiR ONT.